Comorbidities of Psoriasis - Exploring the Links by Network Approach

Sudharsana Sundarrajan, Mohanapriya Arumugam*

Division of Bioinformatics, School of Biosciences and Technology, Vellore Institute of Technology University, Vellore, Tamil Nadu, India

*mohanapriyaa@vit.ac.in

Abstract

Increasing epidemiological studies in patients with psoriasis report the frequent occurrence of one or more associated disorders. Psoriasis is associated with multiple comorbidities including autoimmune disease, neurological disorders, cardiometabolic diseases and inflammatory-bowel disease. An integrated system biology approach is utilized to decipher the molecular alliance of psoriasis with its comorbidities. An unbiased integrative network medicine methodology is adopted for the investigation of diseasome, biological process and pathways of five most common psoriasis associated comorbidities. A significant overlap was observed between genes acting in similar direction in psoriasis and its comorbidities proving the mandatory occurrence of either one of its comorbidities. The biological processes involved in inflammatory response and cell signaling formed a common basis between psoriasis and its associated comorbidities. The pathway analysis revealed the presence of few common pathways such as angiogenesis and few uncommon pathways which includes CCKR signaling map and gonadotrophin-realising hormone receptor pathway overlapping in all the comorbidities. The work shed light on few common genes and pathways that were previously overlooked. These fruitful targets may serve as a starting point for diagnosis and/or treatment of psoriasis comorbidities. The current research provides an evidence for the existence of shared component hypothesis between psoriasis and its comorbidities.

Introduction

Psoriasis is a chronic immune mediated skin disease. The disease presents itself with well circumscribed, red or silvery scaly plaques [1]. The patho-physiology of psoriasis is characterized by increased production of T lymphocytes and up regulation of type 1 T helper cells [2]. Though numerous scientific communities contribute to psoriasis research around the world, the etiology of the disease still remains unidentified. The evolving evidences suggest psoriasis as a complex disorder coordinated by the interplay between multiple genes [3].

The occurrence of one or more disorders in association with a particular disease has recently gained interest in various medicinal divisions including dermatology [4–5]. Multiple observational studies demonstrate the associations between psoriasis and several comorbidities [6–7]. Psoriasis shares common immunological features with many complex disorders such as
cardiovascular disease, diabetes, obesity, depression and inflammatory arthritis [8]. The con-
currence of the disease with other disorders such as Chron’s and Alzheimer’s disease are also
observed [9]. However, the patho-mechanism connecting these systemic comorbidities with
psoriasis remains to be determined. A systematic exploration of the shared component hypoth-
esis existing between the co-morbidities can shed light about the molecular connections aiding
the prevention, early diagnosis and treatment of psoriasis [10]. Network medicine a branch of
systems biology provides a systematic platform to investigate the molecular intricacy of a dis-
ease aiding the identification of new molecular associations among apparently diverse clinical
manifestations [11–12].

The current work aims to decipher the shared component hypothesis between psoriasis and
its five associated common comorbidities which includes myocardial infarction (MI), type II
diabetes (T2DM), obesity, rheumatoid arthritis (RA) and Alzheimer’s disease (AD). The psori-
asis associated comorbidities would be associated at the molecular level by common genes, pro-
teins, biological processes and pathways. The network medicine approach has been utilized to
construct individual diseasomes. The interactomes are explored to identify the biological pro-
cesses and pathways linking psoriasis with its comorbidities.

Materials and Methods

Gene expression data

Gene expression raw data (CEL files) were downloaded from NCBI GEO database [13]. A sin-
gle dataset for each disease category was used for the analysis. For each disease, the dataset was
selected only if it enclosed a minimum of five samples in both disease and control category.
The number of samples and their respective platform details are reported in Table 1.

Microarray gene expression processing

The microarray expression sets were processed individually in a similar way to remove bias.
The raw files from different studies were processed using the bioconductor packages in R [14–
15]. The pre-processing of the microarray data involves background adjustments, quantile nor-
malization and summarization using GeneChip Robust Multiarray Averaging (GCRMA).
Probes with multiple entries were restricted to single entry by taking mean of their expressions.
The probes without any gene affiliations were removed from further analysis. Student’s
unpaired T-test was performed to identify genes that were differentially expressed between the
diseased and normal samples. A threshold of at least 1 fold change and a p-value less than 0.5
were chosen as criteria for selecting the genes. The data sample for RA had entries only for the
diseased category, hence normal samples isolated from synovial tissues of normal donors
(GSE1919) was used for comparison.

Table 1. Gene expression datasets used for the analysis.

| Accession ID | Disease                | Number of samples | Contributor         |
|--------------|------------------------|-------------------|---------------------|
| GSE4757      | Alzheimer’s disease    | 20                | Barth AS et al.,    |
| GSE25724     | Type II diabetes       | 13                | Dominguez V et al.,|
| GSE3585      | Myocardial infarction  | 12                | Barth AS et al.,    |
| GSE9624      | Obesity                | 11                | Aguilera CM et al.,|
| GSE48780     | Rheumatoid arthritis   | 83                | Dennis G Jr et al.,|
| GSE13355     | Psoriasis              | 180               | Gudjonsson JE et al.,|

doi:10.1371/journal.pone.0149175.t001
Diseasome construction

The association between psoriasis and its comorbidities was termed as "diseasome". The two diseases were linked if they share the variations in similar set of genes. Proteins encoded by each differentially expressed gene were identified for the construction of the diseasome. The human proteome interactome was obtained based on the interactions reported by the HPRD server [16]. The strength of the association between two diseases in the diseasome was assessed using molecular comorbidity index (MCI). MCI is defined as:

$$\text{MCI}_{\text{Dis}_1, \text{Dis}_2} = \frac{|(\text{Proteins}_{\text{Dis}_1} \cap \text{Proteins}_{\text{Dis}_2}) \cup (\text{Proteins}_{\text{Dis}_1 \rightarrow \text{Dis}_2}) \cup (\text{Proteins}_{\text{Dis}_2 \rightarrow \text{Dis}_1})|}{|\text{Proteins}_{\text{Dis}_1} \cup \text{Proteins}_{\text{Dis}_2}|}$$

Proteins$_{\text{Dis}_1}$ and Proteins$_{\text{Dis}_2}$ were the proteins associated with disease1 and disease2 respectively. Proteins$_{\text{Dis}_1 \rightarrow \text{Dis}_2}$ Proteins$_{\text{Dis}_2 \rightarrow \text{Dis}_1}$ were the proteins associated with disease1 that show interactions with the proteins associated with disease2 (vice versa for Proteins$_{\text{Dis}_2 \rightarrow \text{Dis}_1}$ Proteins$_{\text{Dis}_1 \rightarrow \text{Dis}_2}$). \(\cap\) was the intersection operator denoting the number of common proteins between the diseases and \(\cup\) operator denote the total number of proteins participating in both the disease categories. The sets represented within the vertical bars indicate their cardinality.

**Functional analysis of the comorbidity proteins.** To explore the significance of biological functions of the differentially expressed proteins in each disease [17] a functional enrichment analysis was carried out using DAVID server [18] and PANTHER classification system [19]. The biological processes and pathways shared by the diseases with psoriasis was assessed using Jaccard coefficient, which is defined as:

$$\text{Jaccard coefficient}_{1, \text{Dis}_2} = \frac{|\text{BP}_{\text{Dis}_1} \cap \text{BP}_{\text{Dis}_2}|}{|\text{BP}_{\text{Dis}_1} \cup \text{BP}_{\text{Dis}_2}|}$$

$$\text{Jaccard coefficient}_{2, \text{Dis}_2} = \frac{|\text{Pathways}_{\text{Dis}_1} \cap \text{Pathways}_{\text{Dis}_2}|}{|\text{Pathways}_{\text{Dis}_1} \cup \text{Pathways}_{\text{Dis}_2}|}$$

The Jaccard coefficient measures the degree of similarity between the psoriasis comorbidities. Dis1 and Dis2 correspond to psoriasis and its comorbidities. Biological process (BP) of Dis1 and Dis2 represents the biological processes contributed by psoriasis and its individual comorbidity respectively, whereas pathways of Dis1 and Dis2 are the biological pathways in which the proteins associated with the comorbidities participate. The calculated measures were visualized as heat-maps constructed using gtools [20].

Results

The differential expression analysis of psoriasis microarray data resulted in 507 differentially expressed genes (DEG) (113-upregulated; 394-downregulated), on submitting the differentially expressed genes of psoriasis transcriptome to DAVID server, around fourteen major disease categories were enriched (Table 2). Each disease category had a minimum of one disease and a maximum of four disease classes. Five diseases based on their common co-occurrence with psoriasis were selected to study their relationship with psoriasis. The comorbidities associated with psoriasis chosen for the study were T2DM, obesity, MI, AD and RA. The association between psoriasis and the five major comorbidities were verified against the published literatures [21–25].

Linking psoriasis with its comorbidities

Independent meta-analysis was carried out for psoriasis and its co-morbidity using their respective microarray expression data. The aim of the meta-analysis was to identify the genes
which were significantly upregulated and down regulated in disease condition when compared with the normal samples [26–27]. The number of genes differentially expressed and associated with five psoriasis comorbidities ranged from 36 (MI) to 2222 (RA) (S1 Table). We constructed a psoriasis specific interactome and utilized the knowledge obtained from the interactome to mine out the commonality between psoriasis and its comorbidities (Fig 1). The psoriasis diseasome constructed using the knowledge obtained above revealed that the comorbidities were connected with psoriasis through shared genes or proteins which interact to form the cellular interactome.

The commonalities between the diseases were assessed based on their interaction patterns. The number of shared genes or proteins in the psoriasis diseasome ranged from 31 (MI) to 312 (T2DM) (Figs 2–5). AD and psoriasis were directly linked through 13 proteins, while the association also occur indirectly through the interaction of 84 proteins. In case of T2DM 26

Table 2. Disease categories associated with psoriasis based on the genes involved.

| Disease class            | Disease | # genes | Genes involved                                                                 |
|--------------------------|---------|---------|--------------------------------------------------------------------------------|
| Musculoskeletal Diseases | RA      | 16      | PLAT, MMP9, TLR2, GGH, PTNP22, CXCR2, MMP1, MMP12, TYMS, IL12RB1, CCR5, CD274, IL1B, SERPINA1, FCGR3B, SELE |
| Neoplasms                | Esophageal cancer | 4 | TYMS, IL8, CXCR2, MMP1 |
| Neoplasms                | Stomach Neoplasms | 5 | TYMS, IL8, CXCR2, MMP1 |
| Neoplasms                | Leiomyoma | 3 | IL12RB1, IL8, IL1B |
| Neoplasms                | Oral cancer | 5 | IL8, MMP9, TGFA, CY2P2E1, MMP1 |
| Virus Diseases           | Hepatitis C | 10 | IFI27, IL12RB1, CCR5, LDLR, IL19, IL1B, OAS1, CXCR2, MX1, IL20 |
| Virus Diseases           | Hepatitis B | 6 | CCR5, OAS3, OAS1, OAS2, MX1, STAT1 |
| Otorhinolaryngologic Diseases | Hearing loss/deafness | 5 | PLAT, SLC26A44, GJB6, ESPN, GJB2 |
| Bacterial Infections and Mycoses | Tuberculosis | 9 | IL12RB1, IL8, TLR2, PTNP22, IL1B, CXCR2, SERPINA1, CYP2E1, STAT1 |
| Nervous System Diseases | Subarachnoid hemorrhage | 5 | MMP9, SERPINA3, IL1B, MMP12, MMP1 |
| Nervous System Diseases | Multiple sclerosis | 15 | IL8, MMP9, CCR1, APOC1, PTNP22, CXCR2, OAS1, IL7R, CXCL10, CCR5, IL1B, CD24, MX1, FCGR3B, SELE |
| Nervous System Diseases | AD | 3 | C3,CD14, DNM3 |
| Digestive System Diseases | Pancreatitis, chronic | 5 | IL8, PRSS2, PRSS3, SERPINA3, IL1B |
| Stomatognathic Diseases | Periodontitis | 9 | PLAT, CCR5, S100A8, MMP9, TLR2, IL1B, SERPINA1, FCGR3B, MMP1 |
| Respiratory Tract Diseases | COPD | 7 | IL8, MMP9, SERPINA3, IL1B, SERPINA1, MMP12, MMP1 |
| Respiratory Tract Diseases | Asthma | 15 | CYP2J2, MMP9, TLR2, CXCR2, EHF, IL12RB2, CCR5, CXCR4, FCGR1B, SERPINA3, FUT3, IL1B, SERPINA1, FUT2, SELE |
| Cardiovascular Diseases | Atherosclerosis | 13 | PLAT, F12, CYP2J2, LDLR, CCR5, SELI, MMP9, APOC1, TLR2, IL1B, FCGR3B, SELE, MMP1 |
| Cardiovascular Diseases | MI | 3 | JAK2, CD14, CCL1 |
| Cardiovascular Diseases | Coronary artery disease | 7 | PLAT, CCR5, LDLR, MMP9, IL1B, SELE, MMP12 |
| Digestive System Diseases | Cirrhosis; pancreatitis | 3 | IL8, IL1B, CYP2E1 |
| Skin and Connective Tissue Diseases | Systemic lupus erythematosus | 9 | CCR5, IL8, CFB, TLR2, PTNP22, IL1B, CXCR2, FCGR3B, SELE |
| Hemic and Lymphatic Diseases | Sarcoidosis; tuberculosis | 3 | IL12RB2, IL12RB1, MMP1 |
| Nutritional and Metabolic Diseases | T2DM | 2 | IL12RB2, IL12RB1 |
| Nutritional and Metabolic Diseases | Obesity | 5 | CXCL1, DPN, NAIP, PAPPA, IL24 |

*Number of genes enriched in each disease category; Diseases are classified based on the MeSH disease hierarchy

doi:10.1371/journal.pone.0149175.t002
proteins directly connected both the diseases and 210 proteins contribute to their interaction via partnering with other proteins. MI and psoriasis were connected directly through 7 proteins and indirectly through 49 proteins. Similarly obesity and psoriasis were connected directly through 24 proteins and indirectly through 11 proteins. RA showed highest percentage of connections. They were connected directly through 201 proteins and indirectly through 386 proteins (Fig 6). The Molecular Comorbidity Index (MCI) which shows the strength of association between psoriasis and its comorbidities was also studied for the better understanding. T2DM leaded the MCI list followed by RA, AD, MI and obesity (Fig 7). To assess the role of direct and indirect contributors to the diseases we further studied the differential expression patterns of the linker proteins.

Direction of expression of the common genes/proteins and linker genes/proteins

The deregulation of common set of genes either in similar or opposite direction can be an underlying cause for the comorbidities. To generate the molecular interpretation of the comorbidities, we compared the direction of dysregulation of the genes shared by psoriasis and its comorbidities with the help of meta-analysis (Fig 8). The DEGs of the comorbidities were compared with DEGs of psoriasis individually. We noted significant overlaps between the DEGs...
upregulated in psoriasis and those downregulated in its comorbidities. Similarly DEGs downregulated in psoriasis were observed to be overlapping with the DEGs upregulated with psoriasis associated comorbidities. Considerable overlap was also observed between DEGs deregulated in same direction between psoriasis and its comorbidities. The DEGs deregulated in the same direction can be treated as putative signatures of the comorbidities while the DEGs deregulated in the opposite direction can contribute to inverse comorbidities. We noted a maximal hit of

Fig 2. Psoriasis diseaseome along with proteins common in AD. Yellow nodes—proteins involved in psoriasis, red nodes—common proteins shared by AD and psoriasis and blue nodes—indirect interactions.

doi:10.1371/journal.pone.0149175.g002
Fig 3. Psoriasis diseasome along with MI proteins. Violet nodes—proteins in psoriasis, red nodes—common proteins shared by MI and psoriasis and blue nodes—indirect interactions.

do:10.1371/journal.pone.0149175.g003
DEGs deregulated in both the direction was from T2DM followed by RA, obesity, AD and MI. Highest number of genes upregulated in the similar direction was reported in T2DM followed by RA, AD, obesity and MI. Similarly the highest number of down-regulated genes in the same direction was seen in RA followed by obesity, AD, T2DM and MI. The highest number of DEG upregulated in opposite direction followed the same pattern of DEGs upregulated in similar direction while the highest number of DEGs down-regulated in opposite direction was observed in AD followed by obesity, T2DM, MI and RA. When the overall DEG count was
Comorbidities of Psoriasis - Network Approach

Fig 5. Psoriasis diseaseome enclosing the protein contributors from obesity. Pink nodes—proteins involved in psoriasis, red nodes—common proteins shared by obesity and psoriasis and blue nodes indicate indirect interactions.

doi:10.1371/journal.pone.0149175.g005

compared the genes expressed in similar directions were high contributing to the positive comorbidity.
Fig 6. Psoriasis diseaseome including proteins from RA. Brown nodes—proteins involvement in psoriasis, red nodes—common proteins shared by RA and psoriasis and blue nodes—indirect interactions.

doi:10.1371/journal.pone.0149175.g006

Exploring the biological processes shared by the proteins in psoriasis diseaseome

To identify the biological functions shared by the psoriasis and its comorbidities, a functional enrichment analysis was performed based on the BP. RA shared the highest number of overlapping BP with psoriasis. The list followed the order of T2DM, obesity, AD and MI starting from
highest to lowest overlapping processes (S2 Table). Defence response, immune response and inflammatory response were enriched in all the comorbidities. Response to wounding showed a similar pattern of expression in almost all the comorbidities except T2DM. Proteins contributing to cell-cell signaling were upregulated in AD, T2DM and RA. Around five biological processes were shared by obesity and RA with connection to psoriasis. To investigate the degree of similarity between psoriasis and its comorbidities, Jaccard coefficient was computed for all the comorbidities (Fig 9A). The highest JC value attributed to obesity followed by T2DM, RA, MI and AD. These observations highlights the critically impaired BP between psoriasis and its comorbidities were from immune mediated processes.

Overlap of identified biological pathways in the psoriasis diseasome

We further investigated the pathways that were common between the psoriasis and its associated comorbidities (S3 Table). Highest number of pathway overlap was observed with RA.
followed by T2DM, obesity, AD and MI. Similar to the BP, the degree of similarity in the pathways between psoriasis and its comorbidities was also assessed using Jaccard coefficient (Fig 9B). Psoriasis shared the highest number of pathways with obesity followed by RA, MI, T2DM and AD. We noted eight pathways were overlapping with all the comorbidities. Angiogenesis, CCKR signaling map, Gonadotrophin-realising hormone receptor pathway, heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway, heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway, inflammation mediated by chemokines and cytokine signaling pathway, integrin signaling pathway and Wnt signaling pathway. Toll like receptor signaling pathway was shared by AD, T2DM, MI and RA. Seven pathways involved in blood coagulation, Cadherin signaling, FGF signaling, Ionotropic glutamate receptor pathway, Metabotropic glutamate receptor group III pathway, Muscarinic acetylcholine receptor 1 and 3 signaling pathway, and Nicotinic acetylcholine receptor signaling pathway were enriched in AD,T2DM, obesity and RA. PDGF signaling pathway was found to be overlapping with T2DM, MI, obesity and RA. It was observed that the biological pathways involved in the comorbid diseases were not only shared by psoriasis but also by the other diseases which are almost unrelated to each other except few. These observations shed lights over the existing associations between the psoriasis with its multi-morbidities at the pathway level.
Discussion

The availability of enormous amount of information from various communities of science makes it essential to appropriately mine out and connect them in a systematic network which allows the creation of new hypothesis. This approach has a probable way to bring about new hypothesis that are not self-evident. In the current work, we adopted an integrative approach by combining the traditional gene expression analysis with the information derived from different databases with the help of bioinformatics.

The network medicine based investigation of five psoriasis comorbidities presented in this work reveals the existence of common genes/proteins, biological process and pathways. In total, these observations highlight the shared component hypothesis of the psoriasis diseasome leading to the discovery of precise molecular connections between psoriasis and its comorbid diseases. The comorbidities occurring with psoriasis have a major impact in the nature of the disease. Yet the precise mechanisms were not evident. To our knowledge, this is the first study utilizing comprehensive and systematic bioinformatics strategy to investigate the shared component hypothesis [28] as a pathogenic mechanism of psoriasis comorbidities.

The proposed network protocol not only provides a global analysis of the proteins but also presents a detailed view on specific proteins and their association with the comorbidity under the study. We noted the appearance of apolipoprotein E (ApoE) in psoriasis and AD. Lipid metabolism is the common term connecting both the disease. ApoE polymorphisms were shown to be associated with both the diseases disrupting the lipid metabolism. When the direction of regulation was considered the gene was downregulated in both the cases as established by the previous reports [29–30]. An elevated level of MCP-1 (CCL2) is observed between psoriasis and MI. The recruitment of inflammatory mediators by MCP-1 formed a common link connecting both the diseases [31]. Leptin, an important regulator of mass of adipose tissue is found to be downregulated in obesity and psoriasis. Many polymorphisms were reported in leptin in both the disease. The gene alters the endothelial cell morphology and causes epithelial hyperplasia in psoriatic patients [32] while in obesity the alteration in the gene lack the control of metabolic regulation of adipocytes [33]. Early growth respons-1 (Egr-1) is upregulated in T2DM and psoriasis. Egr-1 mediated Egr-1/GGPPS/Erk1/2 pathway is one of the pathways involved in insulin resistance under hyperinsulinism condition observed in T2DM [34]. In psoriasis the protein mediates the expression of psoriasin induced by IL-17A via ERK-Egr-1 pathway. Egr-1 is a crucial modulator in Th17-mediated immune response in epidermal keratinocytes [35]. Upregulation and downregulation of various chemokines (CCL4, CCL18, CCL27, CCR1, CCR5, CCR7, CXCL1, CXCL9, CXCL10, CXCL13 and CXCR4) involved in the recruitment of leukocytes and angiogenesis were observed to occur in both psoriasis and RA linking the immune mediated diseases [36–37].

The findings of our work reveal that the psoriasis comorbidities are related at the molecular level that may contribute to their co-occurrences. In this context, the BP annotation identified several process of inflammation such as defence response and immune response which were enriched in all the comorbidities. The pathway annotation also revealed the presence of inflammatory pathways such as inflammation mediated by chemokines and cytokine signaling pathway, integrin signaling pathway and Wnt signaling pathway. The search for inflammatory links was carried out for all the diseases against published literatures.

The production of amyloid-β peptides can activate the innate immune response and evoke AD. Pattern recognition receptor (PRR) such as C1q is involved in complement cascade activation in the brain. The PPRs were also involved in the induction of pro-inflammatory signaling pathways in AD [38]. Various immune related proteins were produced by adipocytes. Increased expression of peroxisome proliferator activated receptor (PPARγ) was observed in
adipose tissue and they are found to be involved in macrophage function [39]. Furthermore, an adipocyte protein, leptin, upregulated in obesity and T2DM can stimulate the activity of macrophage and neutrophil colony-forming cells. The leptin deficiency also imparts impaired lymphoid tissue development. PRRs play a major role in inflammation in obesity and T2DM [40]. The ischemic MI was found to activate pleiotropic inflammatory mediators. IL-8 and CSFs were released during the injury playing a major role in neutrophil recruitment. Neutrophil infiltrations, activation of complement and cytokine cascades were reported by many researchers as inflammatory reactions in MI [31]. Local production of cytokines accounts for systemic clinical manifestation of RA. The cytokines were the products of IL-1, IL-6, colony stimulating factor (CSF-1), GM-CSF and MCP-1. MCP-1 is chemotactic and plays a role in the recruitment of inflammatory leukocytes into the inflamed joints [36, 41]. The occurrence of BP and pathways related to inflammation might form a basic molecular link connecting psoriasis and its comorbidities.

**Conclusion**

Psoriasis and its associated comorbidities highlight psoriasis as a paradigmatic disorder. The comprehensive network-based approach investigated the shared component hypothesis existing between psoriasis with its associated co-morbidities. The findings suggest that the most prevalent psoriasis comorbidities were interlinked through common molecular connections which were evidenced by their shared biological functions and pathways. Significant overlap was observed in the biological process and pathways involved in inflammation in most of the comorbidities establishing a link between them. The work identified few associations in the biological processes and molecular pathways which were previously overlooked in majority of the diseases. The current research also shed light on few multimeric novel targets and pathways which can be targeted to offer diagnosis and/or cure for psoriasis along with its associated comorbidities.

**Supporting Information**

S1 Table. Differentially expressed genes in psoriasis and its associated comorbidities.

S2 Table. Biological process involved in each disease category. The common biological processes between psoriasis and its comorbidities were highlighted.

S3 Table. Biological pathways involved in each disease category. The common biological pathways between psoriasis and its comorbidities are highlighted.

**Acknowledgments**

We thank VIT University for providing the computational facilities.

**Author Contributions**

Conceived and designed the experiments: MPA SS. Performed the experiments: SS MPA. Analyzed the data: SS MPA. Contributed reagents/materials/analysis tools: MPA. Wrote the paper: MPA SS. Idea conceived by: MPA. Analysis done by: SS.
References
1. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012; 7: 385–422. doi:10.1146/annurev-pathol-011811-132448 PMID: 22054142
2. Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immune system changes. Genes Immun. 2006; 8: 1–12. doi:10.1038/sj.gene.6364351 PMID: 17093502
3. Sticherling M. Mechanisms of psoriasis. Drug Discovery Today: Disease Mechanisms. 2005; 2: 275–281. doi:10.1016/j.ddmec.2005.05.019
4. Nalls MA, Saad M, Noyce AJ, Keller MF, Schrag A, Bestwick JP, et al. Genetic comorbidities in Parkinson's disease. Hum Mol Genet. 2014; 23: 831–841. doi:10.1093/hmg/ddt465 PMID: 24057672
5. Melamed RD, Emmett KJ, Madubata C, Rzhefsky A, Rabadian R. Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes. Nat Commun. 2015; 6: 7033. doi:10.1038/ncomms8033 PMID: 25926297
6. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008; 19: 5–21. doi:10.1080/09546630701364768 PMID: 18273720
7. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007; 25: 529–534. doi:10.1016/j.clindermatol.2007.08.006 PMID: 18021889
8. Aurangabadkar S. Comorbidities in psoriasis. Indian Journal of Dermatology, Venereology, and Leprosy. 2013; 79: 10. doi:10.4103/0378-6323.115506
9. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008; 58: 1031–1042. doi:10.1016/j.jaad.2008.01.006 PMID: 18313171
10. Goh K-I, Cusick ME, Valle D, Childs B, Vidal M, Barabási A-L. The human disease network. Proc Natl Acad Sci U S A. 2007; 104: 8685–8690. doi:10.1073/pnas.0701361104 PMID: 17502601
11. Menche J, Sharma A, Kitsak M, Ghiassian SD, Vidal M, Loscalzo J, et al. Uncovering disease-disease relationships through the incomplete interactome. Science. 2015; 347: 1256701. doi:10.1126/science.1256701 PMID: 25700523
12. Barabási A-L, Gulbahce N, Loscalzo J. Network Medicine: A Network-based Approach to Human Disease. Nat Rev Genet. 2011; 12: 56–68. doi:10.1038/nrg2918 PMID: 21164525
13. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002; 30: 207–210. PMID: 11752295
14. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy—analysis of AffymetrixGeneChip data at the probe level. Bioinformatics. 2004; 20: 307–315. doi:10.1093/bioinformatics/btg405 PMID: 14960456
15. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucl Acids Res. 2015; gkv007. doi:10.1093/nar/gkv007
16. Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, Muthusamy B, et al. Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 2004; 32: D497–501. doi:10.1093/nar/gkh070 PMID: 14681466
17. Pavlidis P, Qiu J, Arango V, Mann JJ, Sibille E. Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res. 2004; 29: 1213–1222. PMID: 15176478
18. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007; 35: W169–W175. doi:10.1093/nar/gkm415 PMID: 17576678
19. Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, Muruganujan A, et al. Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res. 2006; 34: W645–660. PMID: 16912892
20. Perez-Llamas C, Lopez-Bigas N. Gitools: Analysis and Visualisation of Genomic Data Using Interactive Heat-Maps. PLoS ONE. 2011; 6: e19541. doi:10.1371/journal.pone.0019541 PMID: 21602921
21. Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet. 2008; 45: 114–118. doi:10.1136/jmg.2007.053595 PMID: 17993580
22. Mcgowan JW, Pearce DJ, Chen J, Richmond D, Barkhishnan R, Feldman SR. The skinny on psoriasis and obesity. Arch Dermatol. 2005; 141: 1601–1602. doi:10.1001/archderm.141.12.1601 PMID: 16365289
23. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296: 1735–1741. doi:10.1001/jama.296.14.1735 PMID: 17032986
24. Bechtel M, Sanders C, Bechtel A. Neurological Complications of Biologic Therapy in Psoriasis. J Clin Aesthet Dermatol. 2009; 2: 27–32. PMID: 20725577
25. Gribble M de G. Rheumatoid Arthritis and Psoriasis. Ann Rheum Dis. 1955; 14: 198–207. PMID: 14388599
26. Sitras V, Fenton C, Acharya G. Gene expression profile in cardiovascular disease and preeclampsia: a meta-analysis of the transcriptome based on raw data from human studies deposited in Gene Expression Omnibus. Placenta. 2015; 36: 170–178. doi: 10.1016/j.placenta.2014.11.017 PMID: 25555499
27. Nazir N, Siddiqui K, Al-Qasim S, Al-Naqeb D. Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis involved in different biochemical pathways. BMC Medical Genomics. 2014; 15: 103. doi: 10.1186/s12881-014-0103-8 PMID: 25280384
28. Park J, Lee D-S, Christakis NA, Barabási A-L. The impact of cellular networks on disease comorbidity. Mol Syst Biol. 2009; 5: 262. doi: 10.1038/msb.2009.16 PMID: 19357641
29. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s disease. Neuron. 2009; 63: 287–303. doi: 10.1016/j.neuron.2009.06.026 PMID: 19679070
30. Al Harthi F, Huraib GB, Zouman A, Arfin M, Tariq M, Al-Asmari A. Apolipoprotein E Gene Polymorphism and Serum Lipid Profile in Saudi Patients with Psoriasis. Disease Markers. 2014; 2014: e239645. doi: 10.1155/2014/239645
31. Köllikzer Frers RA, Bisogno DJ, Montoya SF, Kerzkerg E, Castilla R, Tak PP, et al. Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation. IJC Metabolic & Endocrine. 2015; 6: 43–54. doi: 10.1016/j.ijcme.2015.01.005
32. Karpouzis A, Tripsianis G, Gatzidou E, Veletza S. Assessment of Leptin Gene Polymorphism rs2060713 in Psoriasis Vulgaris. ISRN Dermatol. 2014; 2014: 845272. doi: 10.1155/2014/845272 PMID: 24600521
33. Paracchini V, Pedotti P, Taioli E. Genetics of leptin and obesity: a HuGE review. Am J Epidemiol. 2005; 162: 101–114. doi: 10.1093/aje/kwi174 PMID: 15972940
34. Shen N, Yu X, Pan F-Y, Gao X, Xue B, Li C-J. An early response transcription factor, Egr-1, enhances insulin resistance in type 2 diabetes with chronic hyperinsulinism. J Biol Chem. 2011; 286: 14508–14515. doi: 10.1074/jbc.M110.190165 PMID: 21321112
35. Jeong SH, Kim HJ, Jang Y, Ryu W, Lee H, Kim JH, et al. Egr-1 is a key regulator of IL-17A-induced psoriasin upregulation in psoriasis. Exp Dermatol. 2014; 23: 890–895. doi: 10.1111/exd.12554 PMID: 25256120
36. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007; 7: 429–442. doi: 10.1038/nri2094 PMID: 17525752
37. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003; 423: 356–361. doi: 10.1038/ nature01661 PMID: 12748655
38. Salminen A, Ojala J, Kauppinen A, Kaarniranta K, and Suuronen T. Inflammation in Alzheimer’s disease: Amyloid-β oligomers trigger innate immunity defence via pattern recognition receptors. Progress in Neurobiology. 2009; 87: 171–194. doi: 10.1016/j.pneurobio.2009.01.001 PMID: 19388207
39. Marti A, Marcos A, Martinez JA. Obesity and immune function relationships. Obes Rev. 2001; 2: 131–140. PMID: 12119664
40. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004; 27: 813–823. PMID: 14968310
41. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, et al. Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest. 1994; 93: 921–928. PMID: 8132778